Khondrion presents Phase II KHENERGY trial data

Khondrion presents Phase II KHENERGY trial data

Data supporting Phase III development of KH176 in mitochondrial disease

NIJMEGEN, The Netherlands – Khondrion, a leading clinical-­‐stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY study, a Phase II exploratory trial with oral KH176 in the m.3243A>G multisystem mitochondrial MELAS and MIDD syndromes and mixed phenotypes. The results of the trial were presented by Prof. Jan Smeitink, Khondrion’s CEO, at the Dutch Life Sciences Conference.

“The final reporting of the KHENERGY study is planned for Q1 2018, but encouraged by the results, we wanted to share these preliminary data regarding safety and efficacy now”, said Jan Smeitink.

>> read complete press release

Stay up to date with the latest news!

Newsletter subscribe